Skip to main content

Table 1 Summary of history of tenofovir-treated SIV-infected macaques

From: Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal

Animal number Virus inoculuma Age of virus infection Start of tenofovirb, c CD8+ cell depletiond Temporary tenofovir interruption Permanent tenofovir withdrawal Time of euthanasia
29276 SIVmac-K65R 3 days 3 wks 316 wks None None 736 wks
30577 RT-SHIV 19 months 20 wks 263 wks 289 to 298 wks 552 wks 595 wks
32186 SIVmac251 17 months 2 wks 39 wks 64 to 71 wks 457 wks 498 wks
33088 SIVmac251 12 months 2 wks 2 wks 32 to 39 wks 425 wks 468 wks
33091 SIVmac251 12 months 2 wks 2 wks 32 to 39 wks 425 wks 466 wks
  1. a Animals were inoculated orally or intravenously with wild-type SIVmac251 or RT-SHIV, with the exception of animal 29276, which was inoculated with a K65R SIV isolate (SIVmac385) derived from tenofovir-treated SIVmac251-infected animals, as described previously [10, 11, 13]. All animals had reached undetectable viremia (with sometimes transient blips). With exception of animal 33091, which eventually had a gradual increase in viremia, all other animals maintained undetectable or low viremia even after tenofovir withdrawal.
  2. b Tenofovir was initially given to all these animals at a once-daily regimen of 30 mg/kg body weight, administered subcutaneously, with subsequent dosage reductions to stable maintenance regimens, as described earlier [10, 13, 15].
  3. c Times are expressed as weeks after SIV inoculation.
  4. d Transient CD8+ cell depletion was performed by administration of the monoclonal antibody cM-T807 as described earlier [11].